Navigation Links
Generic Erosion, Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by $1.8 Billion from 2008 to 2018
Date:6/8/2009

Principal Factor Driving the Market Decline Will be Singulair's Loss of Brand Exclusivity, According to a New Report from Decision Resources

WALTHAM, Mass., June 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic and/or branded-generic price erosion, increased product competition and cost consciousness will reduce the asthma drug market from $11.9 billion in 2008 to $10.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Asthma finds that the principal factor that will erode asthma drug sales will be the loss of brand exclusivity of Merck/Kyorin's Singulair, following the market entry of generic versions of the drug (beginning in 2012) in the United States, Europe and Japan. Generic and/or branded-generic erosion of several other key therapies such as GlaxoSmithKline's Advair/Seretide (which is marketed as Adoair in Japan by GlaxoSmithKline/Mitsubishi Tanabe), AstraZeneca's Pulmicort Respules and GlaxoSmithKline's Flovent/Flixotide/Flutide will also constrain the overall asthma market.

The report finds that, with no new blockbuster drug classes in the pipeline through 2018, the asthma market will be defined by product life-cycle management and incremental product development such as new formulations, new combinations and new delivery devices.

"Emerging drugs face the challenge of differentiating themselves from currently available therapies," said Decision Resources Analyst Amy Whiting Ph.D. "Agents that offer improved dosing convenience will effectively capture market share only in those markets where patients and/or third-party payers are willing to pay the price for this feature. Other key players will rely on competitive pricing, incremental gains in safety or improved efficacy to differentiate themselves from competitors."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. More stringent evaluation on the use of generic medications in thoracic transplantation
2. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
3. BCBSNC Customers Save Millions and Stay on Medications with Free Generics Program
4. In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine"
5. National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit
6. Medtipster, a Search Engine With a National Database of Generic Drugs on Discount Programs That Allows Visitors to Search by Zip Code, by Lowest Price, is Now Out of Beta
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Roxicodone(R) Tablets
8. Mail Service and Higher Generic Use Helps Keep Spending in Check, Countering Brand Drug Price Inflation and Specialty Medication Growth
9. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
10. Webcast Alert: Release of Economic Analysis Revealing $734 Billion in Savings Produced by Using Generic Medicines in 1999 - 2008
11. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... NV (PRWEB) , ... May 23, 2017 , ... ... Dental Specialists, are educating patients on peri-implantitis in Las Vegas, NV, ... to receive a custom gum disease consultation and leading care for peri-implantitis, with ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... Horeb, WI (PRWEB) , ... May 23, 2017 , ... ... invited to call Dr. Angela Cotey’s practice to schedule an appointment, with or without ... services, and frequently offers pulpotomy treatments to pediatric patients as a healthy alternative to ...
(Date:5/22/2017)... ... ... Today, Our Urgent Care celebrates the grand opening of its newest urgent ... opening over a month ago, Our Urgent Care Washington has enjoyed serving Franklin County ... Care walk-in clinic is located at 3195 Phoenix Center Dr., Washington, MO 63090 in ...
(Date:5/22/2017)... San Antonio, TX (PRWEB) , ... May 22, 2017 , ... ... It starts with a body squatted, stretched, jumped, toned and shaped through fitness programs. ... And it is, of course, finished off with an irresistible, radiant smile. CDA ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology: